Bannerbild German Brest Group

GBG Research at ESMO Breast Cancer 2019


Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.

#1080: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: pooled analysis based on the GBG database

  • Session: Type: Proffered Paper session; Title: Best abstracts session; 3.05.2019, 16:45 - 17:00 (oral presentation)
  • First author: J. Huober J; Universitätsfrauenklinik Ulm, Germany

#15P: Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: pooled analysis of 484 patients from three prospective multicentre GBG trials

  • Session: Type: Poster display session; Title: Poster lunch; 3.05.2019, 12:15 - 13:00 (poster)
  • First author: P. Jank; Charité Universitaetsmedizin Berlin, Germany

#25P: Expression of ER, PR, HER2 and Ki-67 in the neoadjuvant GeparX trial - comparison of central immunohistochemistry (IHC) with an automated cartridge-based system for mRNA assessment

  • Session: Type: Poster display session; Title: Poster lunch; 03.05.2019; 12:15 - 13:00 (poster)
  • First author: C. Denkert; Institut für Pathologie Philipps-Universität Marburg, Germany

#122TiP: GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo

  • Session: Early breast cancer: Neoadjuvant therapy; 3.05.2019; 12:15 – 13:00 (poster, trial in progress)
  • First author: S. Loibl; GBG, Neu-Isenburg, Germany


  • 31.05.2018 Paper of the month: elderly women and neoadjuvant chemotherapy

    A pooled analysis using data from eight GBG trials (GeparDuo, GeparTrio pilot and main, GeparQuattro, AGO-1, PREPARE, TECHNO; GeparQuinto) that aimed to help selecting appropriately the elderly women who would benefit from neoadjuvant chemotherapy has been published in the Oncotarget.

    Mehr ...
  • 30.04.2018 Paper of the month: survival analysis of the GeparQuinto trial

    We are delighted to inform you that the long-term survival analysis of the neoadjuvant GeparQuinto (GBG 44) phase III trial has been published in the Journal of Clinical Oncology.

    Mehr ...
  • 30.03.2018 Paper of the month: March 2018

    An analysis of 802 women with triple-negative breast cancer (TNBC) from the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) and GeparSixto (GBG 66) trial that investigated the association between the age at TNBC diagnosis and the presence of pathogenic germline BRCA1/2 mutations has been published in the BMC Cancer.

    Mehr ...
  • 13.03.2018 ESMO 2019

    ESMO 2019

    ESMO Breast Cancer congress ist taking place in May 2019 in Berlin, Germany.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd